Skip to content
MedsAcross

Molecule

Diphenhydramine

Also known as diphenhydramine hcl, diphenhydramine hydrochloride
Available on requestDermatology
Presentations
4
Brands
0
Manufacturers
0
Available from stock
0

Diphenhydramine is a histamine-1 receptor antagonist. It is available as injection and oral solution for intramuscular and intravenous use. MedsAcross supplies Diphenhydramine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Histamine-1 Receptor Antagonist, Histamine H1 Receptor Antagonists
ATC classification
D04AA32 Diphenhydramine · Anti-itch skin treatments, subgroup D04A, subgroup D04AAR06AA02 Diphenhydramine · Histamine antagonist, subgroup R06AA
US FDA first approval
4 March 1946
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Intramuscular, Intravenous, Oral
Dosage forms
Injection, Oral solution
Identifiers
UNII 8GTS82S83MRxCUI 3498CAS 58-73-1DrugBank DB01075Q413486

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Diphenhydramine hydrochloride in the oral form is effective for the following indications: Antihistaminic For allergic conjunctivitis due to foods, mild, uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, dermatographism, as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Motion Sickness For active and prophylactic treatment of motion sickness. Antiparkinsonism For parkinsonism (including drug-induced) in the elderly unable to tolerate more potent agents, mild cases of parkinsonism (including drug-induced) in other age groups, in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents. Nighttime Sleep-aid.

Source: US FDA prescribing information

Dosing overview

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT. A single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. The duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours. Adults 25 to 50 mg three or four times daily. The nighttime sleep-aid dosage is 50 mg at bedtime. Pediatric Patients, other than premature infants and neonates 12.5 to 25 mg three or four times daily. Maximum daily dosage not to exceed 300 mg. For physicians who wish to calculate the dose on the basis of body weight or surface area, the recommended dosage is 5 mg/kg/24 hours or 150 mg/m 2 /24 hours. Data are not available on the use of diphenhydramine hydrochloride as a nighttime sleep-aid in children under 12 years.

Source: US FDA prescribing information

Contraindications

Use in Neonates or Premature Infants This drug should not be used in neonates or premature infants. Use in Nursing Mothers Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. Antihistamines are also contraindicated in the following conditions Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.

Source: US FDA prescribing information

Warnings and precautions

Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction. Use in Pediatric Patients In pediatric patients, especially, antihistamines in overdosage may cause hallucinations, convulsions, or death. As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young pediatric patient, particularly, they may produce excitation. Use in the Elderly (approximately 60 years or older) Antihistamines are most likely to cause dizziness, sedation, and hypotension in elderly patients.

Source: US FDA prescribing information

Side effects

The most frequent adverse reactions are underscored. General: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of the mouth, nose and throat. Cardiovascular System: Hypotension, headache, palpitations, tachycardia, extrasystoles. Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis. Nervous System: Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions. GI System: Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation. GU System: Urinary frequency, difficult urination, urinary retention, early menses.

Source: US FDA prescribing information

Interactions

Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

4 presentations of Diphenhydramine, sorted by availability.

MedicineManufacturerRegisterAvailability
Diphenhydramine 50 mg/1 mL injectionIntramuscular, intravenousGeneric name—US FDAAvailable on request
Diphenhydramine 12.5 mg/5 mL oral solutionOralGeneric name—US FDAAvailable on request
Diphenhydramine 500 mg/10 mL injectionIntramuscular, intravenousGeneric name—US FDAAvailable on request
Diphenhydramine 2500 mg/50 mL injectionIntramuscular, intravenousGeneric name—US FDAAvailable on request

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 4 March 1946Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Diphenhydramine in public data. This is not a list of approved uses, see the clinical information.

Questions and answers

Is Diphenhydramine available for export from India?

Yes, on request. MedsAcross lists 4 presentations of Diphenhydramine and sources them for licensed hospitals, importers and physicians against valid import documents.

Is Diphenhydramine approved by the US FDA?

Yes. The US FDA first approved Diphenhydramine on 4 March 1946, according to Drugs@FDA.

Does Diphenhydramine need cold chain shipping?

No listed presentation of Diphenhydramine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Diphenhydramine in?

Diphenhydramine is classified under ATC code D04AA32 (Diphenhydramine).

References

  1. Diphenhydramine HCL prescribing information (Redmont Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 3 August 2026

Request Diphenhydramine for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.